Successful clinical development of anti-obesity agents is aided by characterization of the placebo effect, which can be significant when lifestyle intervention (LSI) accompanies pharmacologic therapy.
Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide
Population pharmacokinetic (PK) and pharmacodynamic (PK/PD) models based on early Phases 1 and 2 data for the new antidiabetic medication exenatide (ex) supported transition from weight-based to…
Population Pharmacokinetics of Paliperidone ER in Healthy Subjects and Patients With Schizophrenia
To develop a population pharmacokinetic (PPK) model for paliperidone extended-release (ER) and to evaluate the influence of selected covariates.
Informatics: the fuel for pharmacometric analysis
The current informal practice of pharmacometrics as a combination art and science makes it hard to appreciate the role that informatics can and should...
Updated Guidance Provided for Fiscal Year 2007 Revenues
Simulations Plus Reports Results Of Annual Meeting
Top 5 Pharmaceutical Company Signs Five-Year Extension Of Services Agreement With Simulations Plus
Contract Signals Long-Term Demand for Simulations Plus' Software and Consulting Services
ANTI-HIV Predictive Models Released by Simulations Plus
Extensions to ADMET Predictor(™) Software Enhance Anti-HIV Activity Discovery Capabilities
Simulations Plus Reports First Quarter FY2007 Financial Results
Record First Quarter Sees Pharmaceutical Revenues Jump 314%
Simulations Plus Announces First Quarter Fiscal Year 2007 Earnings Conference Call
Conference Call to be on Tuesday, January 16, at 4:15 PM EST
Simulations Plus Flagship Software To Aid Government Research Projects
U.S. FDA Licenses GastroPlus(™)
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis
This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment...
Simulations Plus Receives Another Large Pharmaceutical Software License Renewal
Large Pharmaceutical Company Renews Global Software Licenses
Simulations Plus Receives Large Multi-Year Pharmaceutical Software License
Hoffmann-LaRoche Renews Multi-year Software Licenses
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model
An in vitro pharmacodynamic model was used to determine the pharmacokinetic-pharmacodynamic (PK-PD) measure and magnitude most strongly related...
Simulations Plus Releases GastroPlus(™) 5.2
Flagship Software Product Improvements Provide Greater Accuracy and Convenience
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder
A population model was developed with the aim to simultaneously describe risperidone and 9-hydroxyrisperidone pharmacokinetics; to obtain estimates for pharmacokinetic parameters and associated...
Simulations Plus Releases ClassPharmer(™) 4.2
Improvements Provide New Capabilities Requested by User Community
Simulations Plus Reports Preliminary FY2006 Financial Results
Annual Revenues Up 23%, Net Earnings Up 158%
Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract
Novel estrogenic therapies are needed that ameliorate menopausal symptoms and have the bone-sparing effects of endogenous estrogens but do not promote breast or...